Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from the Prevention to Cure

Source :: Plus Company Updates. July 6, 2023
Publication Year :: 2023
Abstract: BEIJING: Brii Biosciences Limited (Brii Bio, we, or the Company, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, [...]

Subjects :: Biotechnology industry -- Licensing agreements
Hepatitis B -- Prevention -- Care and treatment
Vaccines -- Licensing agreements
Company licensing agreement
General interest
News, opinion and commentary

Tools